MedImmune LLC

MedImmune LLC logo
🇺🇸United States
Ownership
Subsidiary
Established
1987-01-01
Employees
5K
Market Cap
-
Website
http://medimmune.com

A Phase II, Trial to Assess the Safety and Tolerability of Influenza Virus Vaccine, CAIV-T in Healthy Children and Adolescents Ages 6 to Less Than 18 Years.

First Posted Date
2005-09-19
Last Posted Date
2012-03-02
Lead Sponsor
MedImmune LLC
Target Recruit Count
240
Registration Number
NCT00192179
Locations
🇧🇪

Catholic University Leuven, Leuven, Belgium

🇧🇪

Zamenhoflaan 12, Schoten, Belgium

🇧🇪

Universiteit Antwerpen, Wilrijk, Belgium

and more 3 locations

Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine (CAIV-T) in Healthy Children

First Posted Date
2005-09-19
Last Posted Date
2012-02-17
Lead Sponsor
MedImmune LLC
Target Recruit Count
173
Registration Number
NCT00192322
Locations
🇺🇸

Division of Allergy Immunology and Infectious Disease, Pittsburgh, Pennsylvania, United States

🇺🇸

Suncoast Clinical Research, Inc., New Port Richey, Florida, United States

Phase II Study to Investigate the Kinetics of the Immune Response Generated by Influenza Virus Vaccine.

First Posted Date
2005-09-19
Last Posted Date
2012-02-14
Lead Sponsor
MedImmune LLC
Target Recruit Count
31
Registration Number
NCT00192309
Locations
🇺🇸

David M. Radin, MD, Stamford, Connecticut, United States

Trial to Evaluate the Immune Response to OPV When Administered Concomitantly With CAIV-T to Healthy Children.

Phase 3
Completed
Conditions
First Posted Date
2005-09-19
Last Posted Date
2006-10-03
Lead Sponsor
MedImmune LLC
Target Recruit Count
2400
Registration Number
NCT00192426

Safety Study of a Monoclonal Antibody to Respiratory Syncytial Virus (RSV) in Children Hospitalized With RSV Infection

First Posted Date
2005-09-19
Last Posted Date
2021-10-08
Lead Sponsor
MedImmune LLC
Target Recruit Count
31
Registration Number
NCT00192504

A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety and Tolerability of Influenza Virus Vaccine,(CAIV-T) in Healthy Infants

Phase 1
Completed
Conditions
First Posted Date
2005-09-19
Last Posted Date
2021-09-13
Lead Sponsor
MedImmune LLC
Target Recruit Count
120
Registration Number
NCT00192348
Locations
🇫🇮

University of Tampere, Tampere, Finland

Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold Adapted (CAIV-T) in Healthy Adults

Phase 3
Completed
Conditions
First Posted Date
2005-09-19
Last Posted Date
2021-09-13
Lead Sponsor
MedImmune LLC
Target Recruit Count
20
Registration Number
NCT00192192
Locations
🇺🇸

Stamford Hospital, Stamford, Connecticut, United States

Trial to Assess the Shedding,Immunogenicity, and Safety of FluMist Administered to Healthy Individuals 5-49 Years of Age

Phase 4
Completed
Conditions
Interventions
First Posted Date
2005-09-19
Last Posted Date
2007-12-28
Lead Sponsor
MedImmune LLC
Target Recruit Count
345
Registration Number
NCT00192140
Locations
🇺🇸

Center for Vaccine Development, Saint Louis, Missouri, United States

🇺🇸

Creighton University Medical Center, Omaha, Nebraska, United States

🇺🇸

University of Virginia, Elson Student Health Center, Charlottesville, Virginia, United States

and more 8 locations

Trial to Demonstrate Equivalent Immunogenicity of CAIV-T and FLUMIST in Healthy Participants

First Posted Date
2005-09-19
Last Posted Date
2007-11-27
Lead Sponsor
MedImmune LLC
Target Recruit Count
890
Registration Number
NCT00192335
Locations
🇺🇸

Kentucky Pediatric/Adult Research, Inc., Bardstown, Kentucky, United States

🇺🇸

R/D Clinical Research, Inc., Lake Jackson, Texas, United States

🇺🇸

Heart of America Research Institute, Shawnee Mission, Kansas, United States

© Copyright 2024. All Rights Reserved by MedPath